Compare NAVN & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAVN | AMRX |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.2B |
| IPO Year | 2025 | 2018 |
| Metric | NAVN | AMRX |
|---|---|---|
| Price | $27.78 | $17.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $20.92 | $15.60 |
| AVG Volume (30 Days) | ★ 2.0M | 1.6M |
| Earning Date | 05-15-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.37 |
| Revenue | ★ $702,265,000.00 | N/A |
| Revenue This Year | $26.56 | $4.48 |
| Revenue Next Year | $22.98 | $7.13 |
| P/E Ratio | ★ N/A | $48.54 |
| Revenue Growth | ★ 30.82 | N/A |
| 52 Week Low | $8.11 | $9.49 |
| 52 Week High | $30.88 | $19.26 |
| Indicator | NAVN | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 52.16 |
| Support Level | $22.15 | $16.61 |
| Resistance Level | $28.08 | $18.58 |
| Average True Range (ATR) | 1.24 | 0.49 |
| MACD | -0.38 | -0.04 |
| Stochastic Oscillator | 34.84 | 49.53 |
Navan Inc is engaged in providing an end-to-end, AI-powered software platform for managing business travel and expense (T&E). The company's platform enables users to manage corporate travel bookings, payments, and expense processes, while providing tools for customers to control and optimize spending and for suppliers to access demand. Geographically, the company operates in the United States, the United Kingdom, and other countries, with the majority of its revenue generated from the United States.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.